A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain

Exclusion Criteria

• •patients who have received a bisphosphonate within 3 weeks from the signing of informed consent;
• •patients receiving concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of dosing;
• •untreated esophagitis or gastric ulcers;
• •recent or pre-scheduled radiotherapy to bone;
• •patients who are pregnant or breast-feeding.